GlaxoSmithKline delivered Q2 sales of £6.5bn (3% above expectations) and core EPS of 24.5p (17% above expectations), up 4% on the comparable quarter last year at CER. There was a good performance across the board although the numbers were flattered by currency effects, positive supply issues and phasing of vaccine tenders.
Strong 2Q And Fresh UK Investment Signal Few Brexit Blues at GSK
GlaxoSmithKline reported a strong second quarter and along with its core EPS guidance upgrade, this adds momentum to its post-Brexit vote boost.

More from Earnings
On Lilly’s Q1 earnings call, CEO David Ricks voiced concerns about the Trump Administration’s tariff policy, which he said could adversely affect Lilly and the industry as a whole.
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.
Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.
MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.